RIBOMIC Inc. and Ajinomoto Co., Inc. announced that they have entered into a joint research agreement to develop technologies for controlling the pharmacokinetics of nucleic acid aptamers in the body. RIBOMIC is promoting research and development, including collaboration with domestic and overseas companies and academia, with the aim of developing technologies for next-generation aptamer drugs. Nucleic acid aptamer compounds are generally modified with polyethylene glycol (hereinafter referred to as "PEG") to enhance their in vivo stability.

However, PEG is known to have problems with its chemical properties, such as its high viscosity and the generation of peroxides, so RIBOMIC has been exploring alternative technologies. The Ajinomoto Group has identified the healthcare field as one of its growth areas, and has outstanding molecular design and compound synthesis technologies through its nucleic acid pharmaceutical and biopharmaceutical CDMO businesses, which are expected to accelerate in the future. In this joint research, will combine proprietary nucleic acid aptamer compound creation and measurement technology and the Ajinomoto Group's antibody-drug conjugate manufacturing technology called AJICAP®?.

By combining with AJICAP®?, aim to establish a technology to control the pharmacokinetics of nucleIC acid aptamers in the Body to solve the above problems.